23andMe to cut 40% of workforce, end therapeutics program
Nov. 11 (UPI) --Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday. The layoffs will impact about 200 employees at the California-based firm and are ...
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
The therapeutic programs of 23andMe include an antibody that restores the ability of the immune system to kill cancer cells. It also has a therapeutic antibody that targets the ULBP6 gene, which suppresses the immune activity of cells.
23andMe ends drug development and slashes staff
23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
23andMe cuts workforce and abandons drug development
Me is restructuring, cutting 40% of its workforce, ending its therapeutics programs, and refocusing on its consumer genetics business. The move, aiming to save $35 million annually, follows financial struggles,
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
23andMe cuts 40% of its workforce, discontinues all therapy programs
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring program.
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
FierceBiotech14h
23andMe shutters cancer drug research programs, lays off 40% of staff
23andMe is shutting down its therapeutics development division, and plans to seek out buyers to find a new home for its ...
STAT1d
The end of 23andMe’s drug discovery dream
23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business ...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 millionDiscontinues development of therapeutics division and ...
Federal law could prevent your 23andMe data deletion, but you should still try
Requesting deletion closes your account permanently and prevents your data from being used in further research (existing ...
ENDPOINTS NEWS11h
23andMe to shut down its ther­a­peu­tics di­vi­sion
Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
Yahoo Finance4d
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe ...
CNET4d
Are You Eligible for Up to $10,000 from 23andMe's Data Breach Settlement?
Personal data of nearly half of the popular genetic testing company's customers -- 6.9 million people -- was exposed in the data breach.